31P - Serum tumor markers CEA, CYFRA 21-1 and anti-p53 in patients with lung cancer
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
F. Lumachi1, F. Mazza2, A. Del Conte3, G.B. Chiara4, S.M.M. Basso4
Lung cancer is one of the most common neoplasms throughout the world, and the most devasting cause of cancer-related death. The 5-year survival rate is very low, accounting for approximately 15%, and it has changed minimally over the past 25 years (1). The poor survival is attrubutable to the fact that the majority of cases are diagnosed when the disease is already metastatic. At this stage, the therapeutic options are restricted to palliative systemic chemotherapy or radiation therapy. Only for patients diagnosed and treated at early stage (Stage I) the 5-year survival is relatively good, ranging between 50% and 80% (2). Several serum tumor markers have been tested in patients with lung cancer, including carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA 21-1), squamous cell carcinoma antigen, neuron-specific enolase (NSE), and more recently anti-p53 antibody circulating markers. The aim of this study was to evaluate the usefulness of serum CEA, CYFRA 21-1, and anti-p53 assay in patents with lung cancer.